Ovid develops small molecule medicines for brain disorders such as epilepsy, seizure disorders and psychosis. OVID reports earnings on Wed, Nov 11, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 15 | Wolfe Research | Initiated | Buy | |
| Oct 5 | Guggenheim | Initiated | Buy | |
| Sep 11 | HC Wainwright & Co. | Maintained | Buy | |
| Aug 3 | Oppenheimer | Maintained | Buy |
Seasonality
How OVID has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.
Whale Options Flow
90DNo whale options trades in OVID in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether OVID is in one of them and how their past OVID trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered OVID in an article yet. Here's the latest on the wider market.
About Ovid Therapeutics
Ovid is a biopharmaceutical company that develops small molecule medicines for disorders of the brain and nervous system. Its work centers on epilepsy, seizure disorders and psychosis, with medicines designed to calm overactive nerve cells. Its programs are in clinical trials, and the company aims to serve patients with seizure and psychiatric conditions that have few treatment options. Ovid is based in New York.
- Headquarters
- New York, NY